Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Return on Equity: 2011-2021

Historic Return on Equity for Neurocrine Biosciences (NBIX) over the last 10 years, with Sep 2021 value amounting to 0.03%.

  • Neurocrine Biosciences' Return on Equity fell 8.00% to 0.03% in Q3 2021 from the same period last year, while for Sep 2021 it was 0.03%, marking a year-over-year decrease of 8.00%. This contributed to the annual value of 0.07% for FY2019, which is 2.00% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Return on Equity stood at 0.03% for Q3 2021, which was down 61.41% from 0.08% recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Return on Equity registered a high of 0.27% during Q2 2020, and its lowest value of -0.74% during Q2 2017.
  • In the last 3 years, Neurocrine Biosciences' Return on Equity had a median value of 0.07% in 2019 and averaged 0.09%.
  • As far as peak fluctuations go, Neurocrine Biosciences' Return on Equity plummeted by 45bps in 2017, and later spiked by 60bps in 2018.
  • Neurocrine Biosciences' Return on Equity (Quarterly) stood at -0.40% in 2017, then skyrocketed by 45bps to 0.05% in 2018, then rose by 1bps to 0.06% in 2019, then grew by 7bps to 0.11% in 2020, then declined by 8bps to 0.03% in 2021.
  • Its Return on Equity stands at 0.03% for Q3 2021, versus 0.08% for Q2 2021 and 0.08% for Q1 2021.